Avail Bio Competitors

Codexis is redefining what is possible in therapeutic development and manufacturing, leading the technology revolution with efficient, high-quality, and commercially proven solutions. The company’s manufacturing platforms consistently outperform legacy methods, enabling the development of therapeutic possibilities that were previously out of reach. With a proven track record, proprietary technology, and unrivalled scientific expertise, Codexis advances beyond conventional boundaries. More than a solutions provider, Codexis serves as a trusted long-term partner, committed to driving progress across complex therapeutic development and manufacturing.

Amyris is a vertically integrated biomanufacturing company that creates specialty molecules for a range of industries, including flavors and fragrances, advanced materials, beauty and personal care, food, and more. Using advanced fermentation technology, Amyris customizes, creates, and manufactures ingredients that enhance lives, protect ecosystems, and take products to the next level of performance. Amyris was founded in 2003 with a bold humanitarian vision to transform access to a lifesaving antimalarial compound using biotechnology. Now, with over two decades of proven commercial success, our proprietary platform is redefining the precision, consistency, and sustainability that is possible with renewable biological chemistry.

Massive Bio is a health-tech company transforming how cancer patients access clinical trials. Operating in 17 countries across North America, Europe, and LATAM, we use proprietary AI technology to match patients to the most appropriate clinical trials—regardless of location, income, or cancer type. We partner with pharmaceutical companies, CROs, and healthcare institutions to accelerate oncology trial enrollment, reduce dropout rates, and deliver real-world evidence. 💠 200K+ patients onboarded 💠 60+ pharma and CRO customers 💠 130+ strategic partners 💠 Founding member of CancerX & participant in the White House Cancer Moonshot Explore how we simplify trial access and optimize recruitment across the oncology ecosystem. 🔗 Learn more: www.massivebio.com Massive Bio was named after three converging revolutions: massive parallel sequencing, massive parallel computing, and the emerging ability to engineer biology itself. We started with symbolic AI before it was fashionable, and evolved into neurosymbolic systems that orchestrate data, computation, and biology—at scale—to bring precision oncology to patients.